Robert Friedlander, MD, is investigating the neuropathology and mechanisms of neurodegeneration in adult-onset neurological diseases. Pre-clinical drug trials in mouse models of neurological disease act as a conduit of therapeutic agents for direct translation to human clinical trials in Huntington’s disease and amyotrophic lateral sclerosis patients.
A major goal of current clinical research is to identify parallels in peripheral and central biomarker detection of disease and manifestations of neuronal dysfunction with translation to potential disease-modifying therapies that are being developed and evaluated in the clinical setting, especially in early stage disease. The goal is to create a data set of multiple markers that can be used with multivariate techniques to develop a unique biochemical signature relating to neurological diseases and to evaluate correlative biomarkers and biomarkers in response to therapy.
Watch the video below from the Clear Thoughts Foundation as Dr. Friedlander talks about his research into developing new strategies for preventing neuro-degenerative diseases, such as dementia.